Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04906213 · ClinicalTrials.gov registry record · Phase 2
CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients
A Phase 2 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT04906213 is a Phase 2 study that was terminated before completion, run by Duke University. The registered enrollment target is 20 participants.
The verdict
NCT04906213, a Phase 2 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
CREST-KT is a single-center, double-blinded, randomized trial of empagliflozin therapy in 72 kidney transplant recipients with (n=36) and without type 2 diabetes (n=36). After evenly dividing patients by type 2 diabetes diagnosis, patients will be randomized 2:1 to empagliflozin 10mg versus placebo.
Interventions
- DRUG Placebo
- DRUG Empagliflozin10Mg Tab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-07-25 |
| Est. Completion | 2026-01-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04906213
The ClinicalTrials.gov registry entry for NCT04906213 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04906213 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04906213 about?
NCT04906213 is a clinical study titled "CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients". CREST-KT is a single-center, double-blinded, randomized trial of empagliflozin therapy in 72 kidney transplant recipients with (n=36) and without type 2 diabetes (n=36). After evenly dividing patients by type 2 diabetes diagnosis, patients will be randomized 2:1 to empagliflozin 10mg versus placebo.
What is the current status of trial NCT04906213?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2022-07-25. Estimated completion is 2026-01-22.
What interventions are being tested in trial NCT04906213?
The interventions under investigation include: Placebo (DRUG), Empagliflozin10Mg Tab (DRUG).
Who is sponsoring clinical trial NCT04906213?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.